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Abstract
Men with prostate cancer are likely to have a long illness and experience psy-
chological distress for which supportive care may be helpful. This systematic
review describes the evidence for effectiveness and cost-effectiveness of support-
ive care for men with prostate cancer, taking into account treatment pathway
and components of interventions. MEDLINE, EMBASE, CINAHL, CENTRAL,
and Psychinfo were searched from inception––July 2013 for randomized con-
trolled trials and controlled trials. Two authors independently assessed risk of
bias and extracted data. Twenty-six studies were included (2740 participants).
Interventions were delivered pre and during (n = 12), short-term (n = 8), and
longer term (18 months) (n = 5) after primary treatment. No interventions
were delivered beyond this time. Few trials recruited ethnic minorities and none
recruited men in same sex relationships. Intervention components included
information, education, health professional discussion, homework, peer discus-
sion, buddy support, cognitive behavioral therapy, cognitive restructuring,
psychoeducation, Reiki and relaxation. Most interventions were delivered for 5–
10 weeks. Risk of bias of trials was assessed as unclear for most domains due to
lack of information. The majority of trials measuring quality of life and depres-
sion found no effect. Relatively few trials measured anxiety, coping skills and
self-efficacy, and the majority found no effect. No cost data were available. Tri-
als of supportive care for men with prostate cancer cover a range of interven-
tions but are limited by population diversity, inconsistent measurement and
reporting of outcomes, and inability to assess risk of bias. Recommendations
on design and conduct of future trials are presented.
Introduction
Prostate cancer is the second most common cancer
worldwide for men, with an estimated 900,000 new cases
diagnosed annually [1]. A large increase in incidence has
been reported in recent years with much of this increase
being attributed to increased prostate-specific antigen
(PSA) testing [2, 3].
Men with prostate cancer are likely to have a long ill-
ness pathway with the greater part being supported by
family, friends, and general practitioners. The National
Cancer Institute defines the goal of supportive care as “to
prevent or treat as early as possible the symptoms of a
disease, side effects caused by treatment of a disease, and
psychological, social, and spiritual problems related to a
disease or its treatment” [4].
Qualitative research tells us that supportive care is
wanted by patients but that it is felt there is a lack
of appropriate support services [5]. A recent survey
covering seven European countries and involving over
1000 men suggests that 81% of the respondents
had some unmet supportive care needs including
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psychological, sexual and health system, and informa-
tion needs [6].
There are four previous relevant reviews [7–10]. One was
a narrative 2010 review focusing on the nature and content
of the 17 included studies, in order to advance understand-
ing of self-management of men with prostate cancer, and
did not focus on the outcome data [7]. Two systematic
reviews looked at psychosocial interventions for men with
prostate cancer [8, 9]. The Chambers 2011 review was nar-
rative and briefly described the outcome data of 21 studies
and concluded that the research was limited on effective
ways to improve adjustment for men with prostate cancer
[8]. The Chien 2012 review sought to combine data from
14 studies in meta-analyses and concluded that psychoso-
cial approaches reduced anxiety and depression [9]. A
recent 2013 Cochrane review and meta-analysis by Parahoo
included 19 psychosocial interventions and concluded that
there was evidence that psychosocial interventions improve
quality of life (QoL) [10].
This review aimed to include supportive care interven-
tions using broader inclusion criteria than these four previ-
ous reviews. Our review comprising 26 trials included
psycho-social and self-management approaches but also
extended to include trials of relaxation, music therapy,
basic information provision, and peer support interven-
tions. This review was designed to take into account the
patient pathway and to identify the individual components
of the interventions with the purpose of determining which
therapeutic components were contributing to the success of
an intervention. To our knowledge, this approach had not
been conducted within a rigorous systematic review of sup-
portive care for men with prostate cancer.
Methods
Eligibility criteria
The review included both randomized controlled or con-
trolled trials (RCTs, CTs) that involved men with a diag-
nosis of prostate cancer; undergoing or having under
gone any type of standard treatment, including active
monitoring. The review did not include trials of men at
risk from prostate cancer, men with advanced cancer or
those who were in the last days of life.
Any intervention was included in the review that could
broadly be defined as supportive, but trials of pharmaceu-
tical interventions including herbal medicine and nutri-
tional supplements, and trials of treatment decision aids
were excluded.
Trials in all languages were included as long as the
abstract was in English in order to assess eligibility. If a
trial involved a mixed population of cancer patients in
which the data for prostate cancer patients could not be
separated it was excluded. The outcomes of interest were
QoL and wellbeing, psychological health, health behaviors,
physical health, and cost-effectiveness data. Outcomes
directly relating to family or partners were not collected.
Information sources and searches
The databases MEDLINE, EMBASE, CINAHL, CENTRAL,
and Psychinfo were searched from their inception to July
2013 using custom-designed search strategies which com-
bined terms of prostate cancer, supportive care interven-
tions, and study type (Appendix S1). The reference lists
of all the included studies were screened for additional
relevant papers and key authors were contacted regarding
any unpublished studies.
Study selection
The references retrieved from the searches were down-
loaded into Endnote X6 and were managed using a cus-
tomized Access 2010 database. All titles and abstracts
from the searches were screened using the eligibility crite-
ria and any studies selected were obtained in full and
assessed in detail by two reviewers in duplicate and inde-
pendently (TM,AH). Reasons for exclusion of all full text
trials were recorded in the Access database.
Data extraction and risk of bias
Data were extracted on study details, participant charac-
teristics, outcome measures, and results. The intervention
components were classified as information-based (infor-
mation, education, health professional discussion, home-
work), peer support (peer discussion, formal buddy system)
or as specific therapeutic approaches (cognitive behavioral
therapy [CBT], cognitive restructuring [CR], psycho-educa-
tion, Reiki, relaxation) (Appendix S2).
One researcher independently extracted data and
assessed risk of bias using the Cochrane Collaboration’s
risk of bias tool and a second checked the accuracy [11].
Each study was assessed in the following domains: ran-
dom sequence generation, allocation concealment, blind-
ing of participants and personnel, blinding of outcome
assessment, incomplete outcome data, selective reporting,
and other possible sources of bias. The terms “high risk,”
“low risk,” and “unclear risk” were used to rate the level
of bias. The decisions of a researcher had to be supported
by evidence or lack of evidence from the published mate-
rial. In all the screening, data extraction and risk of bias
assessment, disagreements were resolved by consensus and
where necessary recourse to a third reviewer. The writing
of the review followed PRISMA guidelines (http://Prisma-
statement.org).
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Synthesis of results
The trials were classified into four groups (Appendix S3)
1 Pre and during primary treatment,
2 Short term after primary treatment (≤6 months),
3 Long term after primary treatment (>6 months),
4 All stages.
Effect sizes were calculated and presented in forest plots
as mean differences or standardized mean differences
when data were available, and when effect sizes for a for-




The review identified 34 papers that described 25 RCTs and
one CT which included a total of 2740 participants [12–45]
(Fig. 1). There were 12 trials conducted pre or during treat-
ment (1173 participants) [12, 14, 16, 18–21, 23, 26–29],
eight conducted in the short term following treatment (824
participants) [30, 31, 33–35, 37–39], five conducted longer
term following primary treatment (743 participants) [40–
44], and one trial which included patients at all stages of
pathway (263 participants) [45] (Tables S1 and S2).
Risk of bias
Overall, information from the included trials needed to
assess risk of bias was poor and therefore the trials were
graded as unclear for most domains. In supportive care
trials, it is not possible to blind participants to their allo-
cation therefore all trials were graded at high risk for this
domain. One trial was a CT and was rated at high risk
for all domains [20]. There were 13 trials which reported
how incomplete data were managed and so they were
rated as low risk, six were rated at unclear risk, and seven
at high risk for this domain Table S2.
Records identified through database 
searching 
(n = 5616 records)
Additional records identified through 
other sources 

















(n = 5618 records)
Records excluded 
(n = 5486 records)
Full-text articles assessed for 
eligibility 
(n = 132 records)
Full-text articles excluded, with reasons 
n = 24 Conference proceeding or trial registry only 
n = 11 Intervention is not relevant
n = 1 Men do not yet have a diagnosis of PC
n = 16 Not an RCT CCT or does not have a control group
n = 25 Outcome for people with prostate cancer not available separate      
from people with other cancers 
n = 10 Outcomes not relevant
n = 10 Protocol
n = 1 We could not obtain paper
(n = 98 records)
Studies included 
n = 26 studies
(34 records) 
Figure 1. PRISMA flow chart of review.
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Provenance and size of trials
Twenty trials were conducted in the United States, two in
Canada, and one each in Northern Ireland, Sweden and
Hong Kong. The U.S. and Canadian trials were generally
funded by government or national research bodies, the
remaining trials were funded by a mixture of public and
private funding, and five of the trials did not declare a
funding source.
In terms of number of trial participants, eight trials
had less than 50, six trials had 50–100, six trials had 101–
200, and the six remaining trials had greater than 200
participants. Seven trials were described as pilot studies
[12, 27, 28, 30, 34, 37, 40], of which two were not
described as “pilot” until the discussion or the main study
paper [30, 34]. Power calculations were reported in four
of the 19 “full scale” trials [20, 21, 23, 45] and in one of
these the participants included prostate cancer and breast
cancer patients in the calculation [20].
Control groups
There were 16 trials that described the control group as
usual, standard, routine care or as a “wait list” [12, 14,
20, 21, 23, 28–31, 33–35, 38–40, 45]. One trial gave no
detail at all [26]. In nine of the trials, the control partici-
pants received services or support in addition to usual
care that were not classified as an intervention [16, 18,
19, 27, 37, 41–44].
Baseline characteristics of participants
The trial participants were on average in their 60s, married
or partnered except for one trial in which 59% of men were
not partnered [27]. There were two trials that did not
report marital status [40, 42]. There were seven trials that
included men from ethnic minority groups [21, 27, 40–45].
In all trials, the majority of participants had received or was
receiving an interventional treatment except in one trial
which recruited patients with an average age of 75 years
who were being actively monitored [30].
Delivery of interventions
There were 14 interventions that were delivered to the indi-
vidual [12, 16, 18–21, 23, 26–30, 38, 39], Eight interven-
tions involved couples or family members. [22, 28, 33, 34,
35, 37, 40, 45] and eight interventions were delivered to
groups [14, 31, 34, 35, 41–44]. Ten of the interventions
were individualized [21, 23, 26–30, 33, 37–39]. The major-
ity of interventions were delivered or facilitated by health
professionals: nurse (6), psychologist (5), mixed-health
professionals (4), “medically trained” (1), researcher (5),
peers (2), volunteers/minimal training (2), and no provider
(1). The majority of trials (22/26) were delivered in person
but some also involved phone calls or emails. There were
four interventions that were delivered exclusively by tele-
phone [21, 27, 30, 40]. Three of the included trials
described interventions with homework [12, 14, 41].
Most of the interventions were short in duration and inten-
sity with a general length of between 5 and 10 weeks, and
weekly meetings of 1–2 h. The range of duration was 2–
48 weeks, with the longer term interventions generally becom-
ing less intense with monthly contact or contact by phone.
Components of interventions
Pre or during treatment
Nine of the 12 trials investigated intervention(s) comprising
at least one informational component [12, 14, 16, 18–20, 23,
26, 28]. Four of these nine trials comprised information-
based components only [16, 18–20, 26, 28]. Six of the 12
trials investigated intervention(s) comprising at least one
specific therapeutic approach [12, 14, 21, 23, 27, 29]. Only
one intervention had a component of peer support [23].
Short term following treatment
The eight trials investigated intervention(s) comprising a
range of components. Four of these eight trials mainly
comprised psychoeducation, education and discussion
with health professionals [30, 31, 33, 37]. The remaining
four trials investigated interventions of peer support facil-
itated by health professionals [34, 35, 38, 39].
Longer term following primary treatment
Four of these five trials described the same stress manage-
ment intervention which comprised information-based,
specific approach (CBT), and peer support components
[41–44]. The remaining trial investigated a coping skill
intervention which comprised informational and specific
approach components [40].
Patients at all stages of pathway
One trial described a psycho-education intervention for
couples first developed for breast cancer patients and
spouses, and modified for prostate cancer [45] (individual
intervention components detailed in Table S1).
Outcomes
The most frequent outcomes measured in these trials
were QoL, depressive symptoms, anxiety, and to a lesser
extent coping and self-efficacy. Only eight of the 26 trials
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distinguished between primary and secondary outcomes
[12, 14, 23, 28, 33, 35, 37, 45] (all individual data are in
Table S1).
Of these eight, only four studies showed improvement
in one of their primary outcomes [12, 23, 33, 35]. None
of the 26 studies explicitly stated a primary endpoint.
Researchers measured and reported a wide range of
other patient outcomes related to these main outcomes
such as uncertainty management, wellbeing, life orienta-
tion, and pain but none showed any improvement.
Quality of life
Overall, 22 of the 26 trials measured QoL with 15 using
general or general cancer QoL scales and 10 using pros-
tate cancer-specific scales. Five of the 22 trials explicitly
stated that QoL was a primary outcome. Seven of the 22
trials reported an improvement in QoL in the interven-
tion group compared with the control group [23, 30, 33–
35, 41, 44]. Two of those 10 trials explicitly stated a pros-
tate cancer-specific QoL scale as a primary outcome mea-
sure [33, 35]. Examination of effects using a forest plot of
standardized mean differences where data were available
indicated that there was no consistent direction of effect
with QoL measures (Fig. S2A–G).
Pre or during treatment
Six of the 12 pre and during treatment trials measured
QoL and used either the Short Form 36-item (SF-36) or
the Functional Assessment of Cancer Therapy–general 27-
item (FACT-G-27) scales [12, 14, 20, 23, 26, 27]. One
study by Parker demonstrated that men given a presurgi-
cal stress management intervention had improved QoL
as measured by the SF-36-physical component score
compared to the control group at 12 months (p=0.0009)
[23].
Short term following treatment
Four of the eight short-term trials measured general QoL,
using SF-36, and a further trial used Cantril’s ladder
(authors own measure using a visual analog scale) [30,
33–35, 39]. One trial measured QoL using the cancer-spe-
cific score of the European Organisation for Research and
Treatment of Cancer Quality of life C30 [31].
Two of the trials reported improvements in general
QoL with a supportive care intervention compared to
control groups. Lepore [31] reported that a psycho-edu-
cational support group had improved mental health
scores using the SF-36 scale compared to controls 2 weeks
postintervention (P = 0.05) [34]. Bailey used Cantril’s
ladder and reported that QoL was greater for men receiv-
ing an uncertainty intervention compared to controls at
10 weeks follow up p = 0.006 [30].
Four of the eight short-term trials reported prostate
cancer-specific QoL and used either the UCLA Prostate
Cancer Index 20-items (UCLA-PC-20) or the Prostate
Cancer Quality of Life Instrument 52-items (PCQoL-52)
[33, 35, 38, 39]. Two of these four trials reported an
improvement. In Lepore et al. [36] reported that group
education with discussion resulted in participants being
less bothered by sexual problems than those in the con-
trol group. Post hoc analyses indicated that sexual bother
within the primary outcome measure of the UCLA-PC-20
index was significantly worse in the control group than in
the education-plus-discussion group (P < 0.01) [35]. In
the Giesler trial, the nurse-led computer program-based
intervention resulted in a reduction in sexual limitation
using the primary outcome measure of the PCQoL-52
compared to the control group at both four and
7 months (P = 0.05; P = 0.02, respectively), and showed
significant reduction in cancer worry at 7 months
(P = 0.03) [33].
Longer term following treatment
Three of the five longer term trials investigating the same
CBT-based intervention measured QoL using the FACT-
G-27 score [42–44]. All three showed some positive effect
on QoL with the intervention pre and postintervention
but only the Traeger study gave data in comparison with
controls (P < 0.01) [42–44]. Campbell measured QoL
using SF-36 and reported no differences between tele-
phone-based coping skills training and control groups
[4].
Both Traeger and Molton also looked at sexual func-
tioning measured by the Expanded Prostate Cancer Index
Composite 26 items and UCLA-PC-20 scales, respectively
[41, 44]. Traeger showed no benefit but Molton reported
a significant improvement in sexual functioning with the
intervention in comparison with the control group
(37.4% vs. 11.5%) [41].
All stages
Northouse measured general (SF-12), cancer-specific
(FACT-G), and prostate cancer-specific (FACT-P) QoL
and reported that there were no improvements for the
men following a supportive education program compared
to the control group [45].
Depressive symptoms, mood, and anxiety
Overall, 14 of the 26 trials used depressive symptoms or
mood as an outcome and three trials measured anxiety
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with a separate measure. In the 14 trials, three showed an
improvement in the intervention group compared with
the control group [23, 38, 39]. One of these three trials
explicitly stated mood as a primary outcome measure
[23]. There were no trials that showed a positive interven-
tion effect on anxiety. Examination of effects using a for-
est plot of standardized mean differences where data were
available indicated that although many of the studies
found no effect on depressive symptoms, mood or anxi-
ety, and the confidence intervals were generally wide they
are tending toward a positive effect (Fig. S3A–C).
Pre and during treatment
Depressive symptoms were measured by the Centre for
Epidemiologic Studies Depression scale (CES-D-20) or
Profile of Mood States (POMS, various numbers of items
used) in seven of the 12 included trials [12, 14, 16, 18–
20, 23]. None of the studies show any significant effect
on depressive symptoms with the exception of the Parker
trial [23]. In this trial of a presurgical stress management
intervention mood (a primary outcome) measured by
POMS-18 item improved in the intervention group com-
pared to the attention control group at 1 week before
surgery p = 0.006. However, by the morning of surgery
there were no differences between the groups [23]. Three
studies investigating relaxation, lifestyle, and education
interventions, respectively, measured anxiety using the
State Trait Anxiety Index-20 items and reported no
improvement in anxiety compared to control groups [12,
14, 28].
Short term following treatment
Seven of the eight included trials measured depressive
symptoms using either the Hospital Anxiety and Depres-
sion Scale 14-item (HADS-14), Geriatric Depression
scale 15-item (GDS-15), CES-D-20, or POMS-various
items [30, 31, 34, 35, 37–39]. Two of the trials showed
a statistically significant improvement albeit short-term
with a supportive care intervention in comparison to a
control group. These two trials were a pilot and a main
trial of a trained buddy support intervention [38, 39].
The pilot trial showed significant improvement in
depressive symptoms at 4 weeks with the intervention
compared to the control group, using the GDS-15
p = 0.014 [38]. In the full-scale trial, the intervention
group had significantly lower depressive symptoms
(GDS-15) at 8 weeks compared with the control group
(P = 0.03).
Two studies found relaxation therapy had no effect on
anxiety (HADS-14) compared to controls [31, 37]. There
were no data from longer term or all stage trials.
Coping skills and self-efficacy
Four trials each used coping and self-efficacy as an outcome
measure [16, 18, 26, 34, 38–40, 45]. In none of these studies
were the outcomes explicitly stated as primary or second-
ary. There were insufficient data to produce forest plots for
the outcomes of coping and self-efficacy.
Pre and during treatment
Two studies found that “concrete information” provided to
participants, prior to their treatment, improved coping
skills as measured by the Sickness Impact Profile-136 item
(SIP-136) compared to a control group over 3 months
(P < 0.02, P < 0.05, respectively) [16, 18]. One of these
studies had an additional intervention group of providing
participants with coping and self-care information which
did not improve coping skills compared to the control
group [18]. In the Templeton trial, the intervention group
received an evidence-based education package. Coping was
measured using the 40-item Jalowiec coping scale, however
the data provided by the authors was not in a usable
format.
Short term after treatment
One study showed that psycho-educational support
increased self-efficacy measured by the investigators own
scale compared with the control group 2 weeks postinter-
vention (P < 0.05) [34]. Self- efficacy measured by the
Stanford Inventory for Cancer Patient Adjustment scale
38-items was not improved by a trained peer buddy inter-
vention compared to controls [38, 39].
Longer term after treatment
There were limited data in the longer term, with one trial
showing that self-efficacy as measured by the Self Efficacy
for Symptom Control Scale–13 items was not improved
by providing supportive educative home visits compared
to controls [40].
All stages
A supportive educational home visit delivered to partici-
pant spouse dyads did not improve coping skills as mea-
sured by the Brief Coping Orientations to Problems
Experienced scale 28-items compared to standard clinic
care [45].
Costs and cost analysis outcomes
None of the included trials described any costs or cost
analysis.
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Discussion
This systematic review included 26 papers describing sup-
portive care interventions for men with prostate cancer.
All of the trials rated poorly overall in terms of risk of
bias or provided too little information for a judgment of
bias to be made. Whilst we recognize that many of the
trials found positive effects of their intervention on spe-
cific outcomes and various follow-up, overall the picture
is more temperate.
The most frequent outcomes measured in these trials
were QoL, depressive symptoms, anxiety, coping, and
self-efficacy. Only seven of the 22 trials measuring QoL
reported an improvement in the intervention group com-
pared with the usual care group. Fourteen of the 26 trials
used depressive symptoms or mood as an outcome, and
three showed an improvement in the intervention group
compared with the control group. Three trials measured
anxiety as an individual measure and no trials showed a
positive intervention effect. There were insufficient data
on coping and self-efficacy.
The interventions were often complex comprising sev-
eral components, for example, Campbell 2007 described
an intervention of education, CR and relaxation therapy
delivered to couples. Our original aim to determine which
of the components of these interventions were contribut-
ing to a positive treatment effect was not possible due to
the limited evidence. However, it was possible to distin-
guish a changing profile of intervention components
across the patient treatment pathway covered in the
included trials. Information and education featured
prominently in the trials of interventions around the time
of treatment. In the short and longer term studies, peer
support and psychologically based intervention compo-
nents dominated. These approaches tally with the sup-
portive care needs described by men with prostate cancer
in qualitative studies [46, 47].
In light of a lack of robust evidence for supportive care
interventions for men with prostate cancer, it is impor-
tant to examine why this was the case. This examination
took into account that the trials considered the patient
pathway in their recruitment and appeared to investigate
appropriate interventions and measure a range of appro-
priate outcomes. Thus, we have compiled a list of recom-
mendations for future trials based on our critique of the
included studies (Box 1).
Limitations of the included studies
Population
Overall there were few trials recruiting ethnic minorities
and there were no studies on younger men with prostate
cancer, no studies explicitly investigating supportive care
needs of men in same sex relationships or men without
partners. Men with different ethnic and or socio-demo-
graphic backgrounds are likely to have different support-
ive care needs [48–50]. Appropriate tailoring of
interventions is not possible without evidence from stud-
ies including or focusing on these groups of men.
Intervention
All the trials included in this review were limited in terms
of timing and duration. Men with prostate cancer were
generally only recruited in the period preceding and fol-
lowing primary treatment. There were no trials recruiting
men beyond 18 months postprimary treatment with the
exception of the Bailey trial [30]. The average length of
an intervention was between 5 and 10 weeks. The few tri-
als of longer duration tended to be low intensity and
tapered. The most likely explanation for this is that long-
term trials are expensive and are likely to be subject to
attrition which will diminish their impact. However,
qualitative data tells us that men’s supportive care needs
continue throughout their lives and therefore we need
more evidence on the longer term care of men to deter-
mine which approaches are likely to be most effective and
cost-effective [46].
There was a range of delivery of the interventions
across individuals, groups of men, and couples. In a
recent review, it was reported that there is a lack of evi-
dence to support the idea that delivery to a group of men
as opposed to an individual was beneficial [10]. Neverthe-
less, qualitative studies show that an informal support
network, including partners and peers is important to
men [46, 47]. It would be useful for future studies to
investigate the format of delivery to provide a more
robust evidence base for this aspect of supportive care.
Control groups
In many of the studies, the control group of usual care
was not defined. In a minority of cases, the control
groups received some of the intervention components.
Without the detailed knowledge of baseline usual care or
what services patients have access to, it is difficult to
assess what an intervention will provide in addition. It is
of note that most of these trials were conducted in the
United States. Other countries are likely to have different
levels of standard care. Thus, all new studies should pro-
vide an adequate description of the usual or standard care
of the patients to give an accurate baseline to additional
supportive care. It is also important to consider that stan-
dards of care are intrinsically linked to socioeconomic sta-
tus, and are likely to differ between affluent and more
deprived areas, and urban and rural environments.
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Outcomes
Data presentation was poor in many papers. Raw data
was often not reported nor available from the authors. In
many cases, the editors of the journals in which they are
published have not required trials to be reported follow-
ing CONSORT guidelines [51]. Although not all journal
editors enforce this, it has made the assessment of risk of
bias difficult and largely the studies are reported as
unclear or at high risk of bias [52].
Conducting systematic reviews and producing evi-
dence-based recommendations relies on good reporting
from clinical trials. Without the essential information and
data being reported, reviewers are obliged to concluded
that the conduct of the trial is of unknown quality when
in fact it may be either at high or at low risk of bias [51,
52, 53].
A qualitative synthesis of studies of men with prostate
cancer describing their experiences of supportive care
and unmet needs has been conducted alongside this
intervention review [47]. In light of these data, it is pos-
sible to suggest that the majority of studies in this
review covered the most relevant outcomes to men with
prostate cancer. The studies in the qualitative review
describe men’s experiences of dealing with reduced QoL
and life-changing side effects, depressive feelings, and
anxiety of waiting for treatment and PSA testing [47].
Although many of the trials measured QoL, some trials
used only a general or cancer QoL measures, with fewer
using a prostate cancer-specific scale. All the QoL
measures used in the trials are in common use and have
been validated. Whilst some QoL issues are common to
all (cancer) patients, the prostate cancer-specific
measures capture the important impact of urinary and
sexual dysfunction which many men with prostate
cancer experience [47].
Overall, the trials that used outcome measures of
depression aimed to look at depressive and anxiety
symptoms as opposed to clinical depression, with only
two trials showing a small percentage of clinically
depressed patients[12, 33] and four studies using clinical
depression or the use of antidepressants as an exclusion
criteria [12, 20, 23, 35]. A retrospective cohort study of
over 50,000 patients with prostate cancer reported that
Box 1. Recommendations for future trials of supportive care interventions for men with prostate cancer
Overall
High quality design and conduct of trials
Local guidance should be followed
http://www.mrc.ac.uk/documents/pdf/good-clinical-practice-in-clinical-trials/ (UK)
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/GuidancesInformationSheetsandNotices/ucm219488.htm (USA)
Power calculations made to ensure trials sufficiently powered relevant to outcomes of interest
http://www-users.york.ac.uk/~mb55/msc/trials/sampsz.htm
Include a nested qualitative investigation into trials to examine participants and partners experiences of the intervention.
Barbour, R. S. 1999. The case for combining qualitative and quantitative approaches in health services research. J. Health Serv. Res.
Policy. 4:39–43.
High quality of reporting of trials
Authors should report the studies following CONSORT guidelines
http://www.consort-statement.org/
Collection of costs and cost/benefit analysis
Whilst determining the effectiveness of an intervention is important, there is little chance of an intervention being implemented by
commissioners of care without relevant accurate costs and cost analysis.
Specifically
Patients
To conduct trials to represent all men in terms of ethnicity, sexuality and partnership status. The majority of trials to date focus on white,
partnered men. The supportive care needs of men are likely to be influenced by men socio-demographic profile [51–53].
To involve or consider the support of a partner close family or friend in trials. Qualitative research tells us that this type of support is
integral to any external support that men with prostate cancer receive [50].
Interventions
To conduct trials that examine all stages of the treatment pathway especially the longer term and patients being active monitored [6].
Control groups
Usual care or control groups need to be well described to be able to determine what the intervention adds.
Outcomes
Standardization of outcomes to allow comparisons across studies and combination of data in systematic reviews [52]
Appropriate, validated outcomes to capture relevant issues for men with prostate cancer. For example, prostate cancer-specific quality of
life measures.
Measures which can capture accurately capture the extent of depression
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8.54% of these men had depression diagnosed using the
ICD-Ninth Revision Clinical Modification [54]. The
authors also report that depression was associated with
higher odds of secondary care use (and costs) and
greater risk of death. Thus, the trials included in the
review most likely underrepresent the prevalence of men
with prostate cancer and depression. Although the mea-
sures in the included trials are well used and validated,
for example, CES-D-20, POMS; they are not adequate
to diagnose major depression. Furthermore, the short
duration (6 months or less) of the majority of the trials
would not capture any new, recurrent or prolonged
depression associated with any ineffective primary or
subsequent treatments.
Previous research by Sharpley et al. proposes five
depressive subtypes within patients with prostate cancer:
melancholic, depressed mood, anhedonic, somatic and
cognitive [55]. These subtypes describe a wide range of
beliefs and attitudes within the diagnosis of depression
and highlights the need for a complementary wide range
of approaches to treat depression in men with prostate
cancer. None of the trials included in this review tackled
depression or low mood in this targeted way.
Coping and self-efficacy are applied outcomes of the
above but unfortunately data were limited and mostly
negative. The less prevalent outcomes were measured by
a mixture of validated, unknown, and author’s own
measures.
The decision was made by the team not to combine
the data in meta-analysis due to heterogeneity. Whilst the
sample of men is homogenous, the interventions are het-
erogeneous in terms of content and when, how, why they
were delivered, for example, Reiki for acute stress, peer
support in cafes. Although there were similar outcomes
and outcome measures used from which data may have
been combined, few data were available in a usable form
or in a similar follow up time. This lack of standardiza-
tion meant that combined data was unlikely to be clini-
cally meaningful. There is currently research based in
Newcastle, UK., as part of the COMET initiative to
develop a set of core outcome measures (COMs) for use
in advanced prostate cancer trials. The development of
such a set of standardized outcomes will progress the evi-
dence base more rapidly [56].
Design
Whilst there were some larger studies, many were small
and most likely not powered sufficiently to determine
differences. Whilst some studies were described as pilot
studies, in those that were not, the majority did
not report a power calculation or the calculation was
inappropriate.
Costs
In order to gain funding for or commissioning of sup-
portive care for men with prostate cancer, cost-benefit
must be determined. There were no costs or cost-effec-
tiveness data in any of the trials included in this review.
Conclusions
Published trials on supportive care for men with prostate
cancer appear to provide appropriate interventions and
measure appropriate outcomes, but provide insufficient
evidence to improve men’s experiences. Trials do not
always use appropriate outcome measures, and have
focused on limited patient groups and stages of the patient
pathway. The majority of trials measuring QoL and depres-
sion found no effect. Relatively few trials measured anxiety,
coping skills and self-efficacy, and the majority found no
effect. No cost data were available. Many of the studies were
small and were likely to be underpowered to detect a differ-
ence. Detailed assessment of these trials has resulted in a list
of recommendations for future trials.
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